FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158602012> ?p ?o ?g. }

• W2158602012 endingPage "336" @default.
• W2158602012 startingPage "334" @default.
• W2158602012 abstract "HomeCirculationVol. 131, No. 4Harnessing the Nitrate–Nitrite–Nitric Oxide Pathway for Therapy of Heart Failure With Preserved Ejection Fraction Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBHarnessing the Nitrate–Nitrite–Nitric Oxide Pathway for Therapy of Heart Failure With Preserved Ejection Fraction Rebecca Vanderpool, PhD and Mark T. Gladwin, MD Rebecca VanderpoolRebecca Vanderpool From the Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA (R.V., M.T.G.); and Division of Pulmonary, Allergy and Critical Care Medicine, UPMC and University of Pittsburgh, Pittsburgh, PA (R.V., M.T.G.). Search for more papers by this author and Mark T. GladwinMark T. Gladwin From the Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA (R.V., M.T.G.); and Division of Pulmonary, Allergy and Critical Care Medicine, UPMC and University of Pittsburgh, Pittsburgh, PA (R.V., M.T.G.). Search for more papers by this author Originally published22 Dec 2014https://doi.org/10.1161/CIRCULATIONAHA.114.014149Circulation. 2015;131:334–336Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 27, 2015: Previous Version 1 Nitrate accumulates in the plasma from oral intake of foods rich in nitrate such as green leafy vegetables and root plants such as beet root or from the intravascular oxidation of nitric oxide (NO), produced by the NO synthase enzymes, to nitrate by oxyhemoglobin. Nitrate is then concentrated in the saliva and reacts with oral commensal bacteria, which contain nitrate reductase enzymes.1 Humans do not possess nitrate reductase enzymes and thus require these bacteria for conversion of nitrate to nitrite. Nitrite is then swallowed and systemically absorbed so that it can be further reduced via single-electron transfer reactions with hemoglobin, myoglobin, neuroglobin, and molybdopterin-containing enzymes (such as xanthine oxidase, aldehyde oxidase, and mARC).2–7 Now referred to as the nitrate-nitrite-NO pathway, this involves a series of oxygen-independent and NO synthase–independent single-electron transfer reactions [Figure (A)].Download figureDownload PowerPointFigure. A, The nitrate–nitrite–nitric oxide (NO) pathway is a series of oxygen-independent and NO synthase–independent single-electron transfer reactions that ultimately facilitate vasodilation. NO therapeutics (nitrate [NO3−] or nitrite [NO2−]) are potentially effective at reversing pathological features of heart failure with preserved ejection fraction (HFpEF). B, Findings from Zamani et al8 suggest that nitrate improves exercise capacity in HFpEF by reducing systemic vascular resistance (SVR) and left ventricular (LV) pulsatile afterload and enhancing cardiac output and oxygen delivery to exercising muscles. C, Webb et al9 found that nitrite significantly dilated both conduit and peripheral arteries. The mechanism by which nitrite dilates conduit arteries is still unknown. ETC indicates electron transport chain; and oxyHb, oxyhemoglobin.Articles see p 371 and p 381Nitrate and nitrite have now been shown to regulate blood pressure, hypoxic vasodilation, mitochondrial efficiency, and exercise performance.2,10–14 Infusions of nitrite have been shown to directly vasodilate the forearm arterial and venous circulation, with significant potentiation during hypoxia.10,14 Systemic infusions of nitrite in dogs exhibit both arteriolar and venous dilation, with more potent effects on the systemic vascular resistance, increasing cardiac output.15 Numerous normal human volunteer studies have now demonstrated that nitrate supplementation can increase exercise efficiency, as defined by total oxygen consumption (o2) for total work performed (Watts).11 In preclinical studies, nitrite has been shown to exhibit therapeutic efficacy in mouse, rat, and sheep models of pulmonary hypertension and mouse models of heart failure.16,17 Additionally, a recent study indicates that dietary supplementation of nitrate reverses the features of metabolic syndrome in endothelial NO synthase–deficient mice.18 Considering the known association between features of the metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), as well as the secondary development of pulmonary vascular disease and exercise intolerance in this disease, a potential therapeutic role for nitrate and nitrite for HFpEF is being considered and evaluated.In this issue of Circulation, Zamani and colleagues8 enrolled 17 subjects with HFpEF in a double-blind, placebo-controlled, crossover trial of a single dose of 12.9 mmol nitrate in 140 mL beet root juice or nitrate-depleted placebo beet root juice to address this question. The rationale for studying HFpEF was based on a number of pathogenic features that might be responsive to NO therapeutics, including abnormal diastolic left ventricular function, reduced exercise tolerance, reduced vasodilatory reserve during exercise, and abnormal skeletal muscle perfusion and function [Figure (A)]. The diagnosis of HFpEF was defined by clinical signs and symptoms of HFpEF on echocardiography, an increased ratio of the early mitral inflow velocity (E) to septal tissue Doppler velocity (e′) >8, and indirect or direct evidence of elevated left ventricular filling pressures. The primary end point of the trial was exercise efficiency, defined by the ratio of total work performed to total oxygen consumed, measured by supine cycle ergometer 2 hours after consumption of the beet root juice or placebo. A number of additional analyses were performed at maximal effort and constant-intensity cardiopulmonary exercise testing, including the evaluation of cardiac function by echocardiography, skeletal muscle deoxygenation during exercise in the calf using near-infrared spectroscopy, forearm postocclusive oxygen consumption rates and reactive hyperemia measured by Doppler ultrasound, and levels of plasma NO metabolites.Although there was no observed significant change in exercise efficiency, the primary end point of the trial, both exercise oxygen consumption and total work performed significantly increased. In addition, the exercise duration significantly increased by almost 1 minute, which was associated with significant reductions in aortic augmentation index, increases in cardiac output, and decreases in calculated systemic vascular resistance. There were no significant changes in near-infrared spectroscopy and postocclusive oxygen consumption or hyperemic flows, although trends for improvements were observed. These findings suggest that nitrate improves exercise capacity in HFpEF by reducing systemic vascular resistance and left ventricular pulsatile afterload and enhancing cardiac output and oxygen delivery to exercising muscles [Figure (B)].Although these findings are provocative and the trial was well designed, a major limitation is a reliance on secondary end points, with a primary end point that is not consistent with a number of studies on the published effects of nitrate in normal volunteers.11 A central effect observed with nitrate repletion in prior studies was the effect on improved exercise efficiency, characterized by an increase in work performed for any level of oxygen consumption.11 On the other hand, the finding of an increase in exercise duration has been reported, particularly in disease states such as chronic obstructive pulmonary disease.19 The study also uses noninvasive measurements of hemodynamics and a single oral dose of nitrate, with no long-term follow-up to evaluate long-term effects on both exercise capacity or signs and symptoms of heart failure and the metabolic syndrome.How Does Nitrite Vasodilate? Implications for HFpEF TherapyA second study by Omar and colleagues9 published in this issue of Circulation explored in more detail the pharmacological properties of nitrite in the human circulation, reporting for the first time that nitrite vasodilates not only the arteriolar and venous circulation, as previously described, but also the conduit blood vessels, an effect similar to that observed with nitroglycerin. This effect was associated with a reduction in central systolic blood pressure, augmentation index, and pulsed-wave velocity, which represent hemodynamic effects that might show therapeutic promise in the setting of HFpEF [Figure (C)]. Interestingly, although the effects of nitrite on arteriolar blood flow (measured by venous occlusion strain-gauge plethysmography) were potentiated by hypoxia, as previously described and quite distinct from the effects of nitroglycerin,14 the vasodilatory effects on the conduit arteries were actually inhibited under hypoxia and hyperoxia conditions.The mechanism for this normoxic nitrite bioactivation remains uncertain, but the lack of significant deoxygenation of hemoglobin or myoglobin and the dominant oxidase activities of molybdopterin enzymes under normoxic conditions suggest that these pathways are unlikely to account for this conduit vasodilatory effect. Omar and colleagues9 infused 2 drugs to test the mechanisms for nitrite bioactivation in conduit arteries. The first was reloxifene, an inhibitor of aldehyde oxidize, classically considered an oxidase that generates superoxide but recently shown also to possess nitrite reductase activity under hypoxic conditions.20,21 Infusion of the aldehyde oxidase inhibitor actually increased nitrite-dependent conduit artery vasodilation, suggesting that this enzyme is in fact generating superoxide, which can scavenge NO. Reduced production of superoxide likely increases NO bioavailability from nitrite and increases vasodilator potency, similar to previous observations with inhibition of xanthine oxidase during nitrite infusions in the human forearm.10 The authors next tested infusions of acetazolamide, an inhibitor of carbonic anhydrase, also proposed to be a nitrite reductase (anhydrase).22 This inhibitor also increased the potency of nitrite. Although Aamand and colleagues22 have proposed that classic inhibitors of carbonic anhydrase can paradoxically increase nitrite reduction by this enzyme, we have recently shown that acetazolamide and dorzolamide reduce nitrite conversion to NO by carbonic anhydrase23, raising questions about this pathway in nitrite reduction. Clearly, carbonic anhydrase and aldehyde oxidase are major enzymes mediating nitrite conversion to NO, and more work is required to explore pathways for the observed conduit artery normoxic vasodilation.Nitrite is an inorganic salt (NO2−) and must be clearly differentiated from the organic nitrates such as nitroglycerin that are characterized by covalently bound nitro (NO2-R) groups adducted to carbon-based small molecules. The latter species require enzymatic metabolism to form NO and nitrite, and this enzymatic process is subject to tolerance. Studies in humans and primates suggest that nitrite is not subject to enzymatic tolerance and continues to produce sustained vasodilation with long-term exposure.10 This lack of enzymatic tolerance suggests potential greater therapeutic potential for nitrite as a long-term therapy for HFpEF. These new studies now clarify that nitrite drives pharmacological arteriolar, venous, and conduit artery vasodilation, all effects that may prove beneficial as a long-term therapy for HFpEF. More study is required to understand how nitrite dilates conduit arteries under normoxic conditions and to test therapeutic effects of more long-term treatments with nitrate or nitrite in patients with HFpEF.DisclosuresDr Gladwin is a coinventor on a National Institutes of Health government patent for the use of nitrite salts in cardiovascular diseases. Dr Gladwin consults with Aires/MAST Pharmaceuticals on the development of a phase II proof-of-concept trial using inhaled nitrite for pulmonary hypertension. Dr Vanderpool reports no conflicts.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Mark T. Gladwin, MD, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, E1244 BST 200 Lothrop St, Pittsburgh, PA 15213. E-mail [email protected]References1. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics.Nat Rev Drug Discov. 2008; 7:156–167. doi: 10.1038/nrd2466.CrossrefMedlineGoogle Scholar2. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation.Nat Med. 2003; 9:1498–1505. doi: 10.1038/nm954.CrossrefMedlineGoogle Scholar3. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, Darley-Usmar VM, Gladwin MT. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration.Circ Res. 2007; 100:654–661. doi: 10.1161/01.RES.0000260171.52224.6b.LinkGoogle Scholar4. Tiso M, Tejero J, Basu S, Azarov I, Wang X, Simplaceanu V, Frizzell S, Jayaraman T, Geary L, Shapiro C, Ho C, Shiva S, Kim-Shapiro DB, Gladwin MT. Human neuroglobin functions as a redox-regulated nitrite reductase.J Biol Chem. 2011; 286:18277–18289. doi: 10.1074/jbc.M110.159541.CrossrefMedlineGoogle Scholar5. Zhang Z, Naughton DP, Blake DR, Benjamin N, Stevens CR, Winyard PG, Symons MC, Harrison R. Human xanthine oxidase converts nitrite ions into nitric oxide (NO).Biochem Soc Trans. 1997; 25:524S.CrossrefMedlineGoogle Scholar6. Sparacino-Watkins CE, Tejero J, Sun B, Gauthier MC, Thomas J, Ragireddy V, Merchant BA, Wang J, Azarov I, Basu P, Gladwin MT. Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2.J Biol Chem. 2014; 289:10345–10358. doi: 10.1074/jbc.M114.555177.CrossrefMedlineGoogle Scholar7. Kim-Shapiro DB, Gladwin MT. Mechanisms of nitrite bioactivation.Nitric Oxide. 2014; 38:58–68. doi: 10.1016/j.niox.2013.11.002.CrossrefMedlineGoogle Scholar8. Zamani P, Rawat D, Prithvi S-K, Geraci S, Bhuva R, Konda P, Doulias P-T, Ischiropoulos H, Townsend R, Margulies K, Cappola T, Poole D, Chirinos J. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction.Circulation. 2015; 131:371–380.LinkGoogle Scholar9. Omar S, Fok H, Tilgner K, Nair A, Hunt J, Jiang B, Taylor P, Chowienczyk P, Webb A. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures.Circulation. 2015; 131:381–389.LinkGoogle Scholar10. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, Oldfield EH, Cannon RO, Schechter AN, Gladwin MT. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation.Circulation. 2007; 116:1821–1831. doi: 10.1161/CIRCULATIONAHA.107.712133.LinkGoogle Scholar11. Jones AM. Dietary nitrate supplementation and exercise performance.Sports Med. 2004; 44(suppl 1):S35–S45.CrossrefGoogle Scholar12. Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO, Weitzberg E. Dietary inorganic nitrate improves mitochondrial efficiency in humans.Cell Metab. 2011; 13:149–159. doi: 10.1016/j.cmet.2011.01.004.CrossrefMedlineGoogle Scholar13. Kapil V, Haydar SM, Pearl V, Lundberg JO, Weitzberg E, Ahluwalia A. Physiological role for nitrate-reducing oral bacteria in blood pressure control.Free Radic Biol Med. 2013; 55:93–100. doi: 10.1016/j.freeradbiomed.2012.11.013.CrossrefMedlineGoogle Scholar14. Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, Thomas P, Ashrafian H, Born GV, James PE, Frenneaux MP. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans.Circulation. 2008; 117:670–677. doi: 10.1161/CIRCULATIONAHA.107.719591.LinkGoogle Scholar15. Minneci PC, Deans KJ, Shiva S, Zhi H, Banks SM, Kern S, Natanson C, Solomon SB, Gladwin MT. Nitrite reductase activity of hemoglobin as a systemic nitric oxide generator mechanism to detoxify plasma hemoglobin produced during hemolysis.Am J Physiol Heart Circ Physiol. 2008; 295:H743–H754. doi: 10.1152/ajpheart.00151.2008.CrossrefMedlineGoogle Scholar16. Sparacino-Watkins CE, Lai YC, Gladwin MT. Nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics.Circulation. 2012; 125:2824–2826. doi: 10.1161/CIRCULATIONAHA.112.107821.LinkGoogle Scholar17. Baliga RS, Milsom AB, Ghosh SM, Trinder SL, Macallister RJ, Ahluwalia A, Hobbs AJ. Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase.Circulation. 2012; 125:2922–2932. doi: 10.1161/CIRCULATIONAHA.112.100586.LinkGoogle Scholar18. Carlström M, Larsen FJ, Nyström T, Hezel M, Borniquel S, Weitzberg E, Lundberg JO. Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice.Proc Natl Acad Sci U S A. 2010; 107:17716–17720. doi: 10.1073/pnas.1008872107.CrossrefMedlineGoogle Scholar19. Berry MJ, Justus NW, Hauser JI, Case AH, Helms CC, Basu S, Rogers Z, Lewis MT, Miller GD. Dietary nitrate supplementation improves exercise performance and decreases blood pressure in COPD patients [published online ahead of print October 27, 2014].Nitric Oxide. doi: 10.1016/j.niox.2014.10.007. http://www.sciencedirect.com/science/article/pii/S1089860314004650.Google Scholar20. Li H, Cui H, Kundu TK, Alzawahra W, Zweier JL. Nitric oxide production from nitrite occurs primarily in tissues not in the blood: critical role of xanthine oxidase and aldehyde oxidase.J Biol Chem. 2008; 283:17855–17863. doi: 10.1074/jbc.M801785200.CrossrefMedlineGoogle Scholar21. Li H, Kundu TK, Zweier JL. Characterization of the magnitude and mechanism of aldehyde oxidase-mediated nitric oxide production from nitrite.J Biol Chem. 2009; 284:33850–33858. doi: 10.1074/jbc.M109.019125.CrossrefMedlineGoogle Scholar22. Aamand R, Dalsgaard T, Jensen FB, Simonsen U, Roepstorff A, Fago A. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation.Am J Physiol Heart Circ Physiol. 2009; 297:H2068–H2074. doi: 10.1152/ajpheart.00525.2009.CrossrefMedlineGoogle Scholar23. Liu C, Wajih N, Liu X, Basu S, Janes J, Marvel M, Keggi C, Helms CC, Lee AN, Belanger AM, Diz DI, Laurienti P, Caudell DL, Wang J, Gladwin MT, Kim-Shapiro DB. Mechanisms of human erythrocytic bioactivation of nitrite [published online ahead of print December 3, 2014].J Biol Chem. doi: 10.1074/jbc.M114.609222. http://www.jbc.org/content/early/2014/12/03/jbc.M114.609222.long.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By O'Gallagher K and Webb A (2022) Organic and dietary nitrates, inorganic nitrite, nitric oxide donors, and soluble guanylate cyclase stimulation Textbook of Arterial Stiffness and Pulsatile Hemodynamics in Health and Disease, 10.1016/B978-0-323-91391-1.00051-0, (807-828), . Chirinos J (2022) Arterial stiffness and pulsatile hemodynamics in heart failure Textbook of Arterial Stiffness and Pulsatile Hemodynamics in Health and Disease, 10.1016/B978-0-323-91391-1.00036-4, (565-589), . Reddy Y, Stewart G, Obokata M, Koepp K and Borlaug B (2021) Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction , European Journal of Heart Failure, 10.1002/ejhf.2093, 23:5, (814-823), Online publication date: 1-May-2021. Kaur G and Krishan P (2020) Understanding Serotonin 5-HT2A Receptors-regulated cellular and molecular Mechanisms of Chronic Kidney Diseases, Renal Replacement Therapy, 10.1186/s41100-020-00268-x, 6:1, Online publication date: 1-Dec-2020. MANOURAS A and LUND L (2020) Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction: Treating Resistance, Impedance, and Compliance, Journal of Cardiac Failure, 10.1016/j.cardfail.2020.07.003, 26:8, (662-663), Online publication date: 1-Aug-2020. Gui Y, Chen J, Hu J, Ouyang M, Deng L, Liu L, Sun K, Tang Y, Xiang Q, Xu J, Zhu L, Peng Z, Zou P, Li B, Zheng Z and Xu D (2020) Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction, Cardiovascular Drugs and Therapy, 10.1007/s10557-020-06980-4, 34:4, (503-513), Online publication date: 1-Aug-2020. Tang Y, Liu Y, Yin B, Guo Y, Liu Y, Zhao Y, Wang Y, Cao Y, Feng J, Leng J and Huang C (2019) BaiJiu Increases Nitric Oxide Bioactivity of Chinese Herbs Used to Treat Coronary Artery Disease Through the NO3−–NO2−–NO Pathway, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0000000000000715, 74:4, (348-354), Online publication date: 1-Oct-2019. Chirinos J (2018) The Nitrate-Nitrite-NO Pathway as a Novel Therapeutic Target in Heart Failure with Reduced Ejection Fraction, Journal of Cardiac Failure, 10.1016/j.cardfail.2017.12.001, 24:2, (74-77), Online publication date: 1-Feb-2018. Chirinos J, Londono-Hoyos F, Zamani P, Beraun M, Haines P, Vasim I, Varakantam S, Phan T, Cappola T, Margulies K, Townsend R and Segers P (2017) Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction, European Journal of Heart Failure, 10.1002/ejhf.885, 19:11, (1507-1515), Online publication date: 1-Nov-2017. Chirinos J (2017) Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations, Journal of Cardiovascular Translational Research, 10.1007/s12265-017-9736-2, 10:3, (261-274), Online publication date: 1-Jun-2017. Reddy Y, Lewis G, Shah S, LeWinter M, Semigran M, Davila-Roman V, Anstrom K, Hernandez A, Braunwald E, Redfield M and Borlaug B (2017) INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction), Circulation: Heart Failure, 10:5, Online publication date: 1-May-2017. Liu X, El-Mahdy M, Boslett J, Varadharaj S, Hemann C, Abdelghany T, Ismail R, Little S, Zhou D, Thuy L, Kawada N and Zweier J (2017) Cytoglobin regulates blood pressure and vascular tone through nitric oxide metabolism in the vascular wall, Nature Communications, 10.1038/ncomms14807, 8:1, Online publication date: 1-Apr-2017. Mills C, Khatri J, Maskell P, Odongerel C and Webb A (2016) It is rocket science - why dietary nitrate is hard to ‘beet’! Part II : further mechanisms and therapeutic potential of the nitrate-nitrite-NO pathway , British Journal of Clinical Pharmacology, 10.1111/bcp.12918, 83:1, (140-151), Online publication date: 1-Jan-2017. Chirinos J, Akers S, Trieu L, Ischiropoulos H, Doulias P, Tariq A, Vasim I, Koppula M, Syed A, Soto‐Calderon H, Townsend R, Cappola T, Margulies K and Zamani P (2016) Heart Failure, Left Ventricular Remodeling, and Circulating Nitric Oxide Metabolites, Journal of the American Heart Association, 5:10, Online publication date: 3-Oct-2016.Borlaug B, Melenovsky V and Koepp K (2016) Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction, Circulation Research, 119:7, (880-886), Online publication date: 16-Sep-2016.Shah S, Kitzman D, Borlaug B, van Heerebeek L, Zile M, Kass D and Paulus W (2016) Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction, Circulation, 134:1, (73-90), Online publication date: 5-Jul-2016. Guazzi M and Labate V (2016) Group 2 PH: Medical Therapy, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2016.06.003, 59:1, (71-77), Online publication date: 1-Jul-2016. Eggebeen J, Kim-Shapiro D, Haykowsky M, Morgan T, Basu S, Brubaker P, Rejeski J and Kitzman D (2016) One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction, JACC: Heart Failure, 10.1016/j.jchf.2015.12.013, 4:6, (428-437), Online publication date: 1-Jun-2016. Lai Y, Tabima D, Dube J, Hughan K, Vanderpool R, Goncharov D, St. Croix C, Garcia-Ocaña A, Goncharova E, Tofovic S, Mora A and Gladwin M (2016) SIRT3–AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction, Circulation, 133:8, (717-731), Online publication date: 23-Feb-2016. Ling W, Lau Y, Murugan D, Vanhoutte P and Mustafa M (2015) Sodium nitrite causes relaxation of the isolated rat aorta: By stimulating both endothelial NO synthase and activating soluble guanylyl cyclase in vascular smooth muscle, Vascular Pharmacology, 10.1016/j.vph.2015.05.014, 74, (87-92), Online publication date: 1-Nov-2015. Paulus W and van Heerebeek L (2015) Ancient Gunpowder and Novel Insights Team Up Against Heart Failure With Preserved Ejection Fraction, Journal of the American College of Cardiology, 10.1016/j.jacc.2015.08.028, 66:15, (1683-1686), Online publication date: 1-Oct-2015. January 27, 2015Vol 131, Issue 4 Advertisement Article InformationMetrics © 2014 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.114.014149PMID: 25533965 Originally publishedDecember 22, 2014 KeywordsEditorialsnitratesnitric oxidePDF download Advertisement SubjectsVascular Biology" @default.
• W2158602012 created "2016-06-24" @default.
• W2158602012 creator A5007944034 @default.
• W2158602012 creator A5066563916 @default.
• W2158602012 date "2015-01-27" @default.
• W2158602012 modified "2023-09-25" @default.
• W2158602012 title "Harnessing the Nitrate–Nitrite–Nitric Oxide Pathway for Therapy of Heart Failure With Preserved Ejection Fraction" @default.
• W2158602012 cites W1511302815 @default.
• W2158602012 cites W2000501615 @default.
• W2158602012 cites W2004691285 @default.
• W2158602012 cites W2012172244 @default.
• W2158602012 cites W2017907872 @default.
• W2158602012 cites W2027419908 @default.
• W2158602012 cites W2033357754 @default.
• W2158602012 cites W2056934771 @default.
• W2158602012 cites W2068477954 @default.
• W2158602012 cites W2074172668 @default.
• W2158602012 cites W2078382982 @default.
• W2158602012 cites W2086187832 @default.
• W2158602012 cites W2087384948 @default.
• W2158602012 cites W2094188595 @default.
• W2158602012 cites W2095374517 @default.
• W2158602012 cites W2112453730 @default.
• W2158602012 cites W2113170838 @default.
• W2158602012 cites W2150393833 @default.
• W2158602012 cites W2153373550 @default.
• W2158602012 cites W2157253654 @default.
• W2158602012 cites W2401559749 @default.
• W2158602012 doi "https://doi.org/10.1161/circulationaha.114.014149" @default.
• W2158602012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25533965" @default.
• W2158602012 hasPublicationYear "2015" @default.
• W2158602012 type Work @default.
• W2158602012 sameAs 2158602012 @default.
• W2158602012 citedByCount "21" @default.
• W2158602012 countsByYear W21586020122015 @default.
• W2158602012 countsByYear W21586020122016 @default.
• W2158602012 countsByYear W21586020122017 @default.
• W2158602012 countsByYear W21586020122018 @default.
• W2158602012 countsByYear W21586020122019 @default.
• W2158602012 countsByYear W21586020122020 @default.
• W2158602012 countsByYear W21586020122021 @default.
• W2158602012 countsByYear W21586020122022 @default.
• W2158602012 crossrefType "journal-article" @default.
• W2158602012 hasAuthorship W2158602012A5007944034 @default.
• W2158602012 hasAuthorship W2158602012A5066563916 @default.
• W2158602012 hasBestOaLocation W21586020121 @default.
• W2158602012 hasConcept C126322002 @default.
• W2158602012 hasConcept C164705383 @default.
• W2158602012 hasConcept C178790620 @default.
• W2158602012 hasConcept C185592680 @default.
• W2158602012 hasConcept C2776179834 @default.
• W2158602012 hasConcept C2776384668 @default.
• W2158602012 hasConcept C2778198053 @default.
• W2158602012 hasConcept C519581460 @default.
• W2158602012 hasConcept C71924100 @default.
• W2158602012 hasConcept C78085059 @default.
• W2158602012 hasConceptScore W2158602012C126322002 @default.
• W2158602012 hasConceptScore W2158602012C164705383 @default.
• W2158602012 hasConceptScore W2158602012C178790620 @default.
• W2158602012 hasConceptScore W2158602012C185592680 @default.
• W2158602012 hasConceptScore W2158602012C2776179834 @default.
• W2158602012 hasConceptScore W2158602012C2776384668 @default.
• W2158602012 hasConceptScore W2158602012C2778198053 @default.
• W2158602012 hasConceptScore W2158602012C519581460 @default.
• W2158602012 hasConceptScore W2158602012C71924100 @default.
• W2158602012 hasConceptScore W2158602012C78085059 @default.
• W2158602012 hasIssue "4" @default.
• W2158602012 hasLocation W21586020121 @default.
• W2158602012 hasLocation W21586020122 @default.
• W2158602012 hasOpenAccess W2158602012 @default.
• W2158602012 hasPrimaryLocation W21586020121 @default.
• W2158602012 hasRelatedWork W1964604653 @default.
• W2158602012 hasRelatedWork W1972194921 @default.
• W2158602012 hasRelatedWork W2003722412 @default.
• W2158602012 hasRelatedWork W2091139515 @default.
• W2158602012 hasRelatedWork W2345946497 @default.
• W2158602012 hasRelatedWork W2355594703 @default.
• W2158602012 hasRelatedWork W2467153938 @default.
• W2158602012 hasRelatedWork W2992023086 @default.
• W2158602012 hasRelatedWork W3033076790 @default.
• W2158602012 hasRelatedWork W4378619662 @default.
• W2158602012 hasVolume "131" @default.
• W2158602012 isParatext "false" @default.
• W2158602012 isRetracted "false" @default.
• W2158602012 magId "2158602012" @default.
• W2158602012 workType "article" @default.